Fiscal Year End: March 31 (HOYA calls FY ending March 2026 "FY25") Most Recent Results: Q3 FY25 (Oct-Dec 2025), reported January 30, 2026 Next Full-Year Results: May 13, 2026

Download Manifest

File	Type	Period	Size	Path
7741-Q3-FY2026-presentation.pdf	Q3 Earnings Presentation (English)	Oct-Dec 2025	3.1M	interim/
7741-Q3-FY2026-tanshin.pdf	Q3 Tanshin	Oct-Dec 2025	578K	interim/

Source: HOYA IR. All amounts in ¥B unless noted.

---

Section A: Filing Monitor

1. Filing Activity Overview

Date Filed	Filing Type	Description	Source
Feb 2, 2026	Q3 Earnings Call Transcript	English transcript of Jan 30 call	HOYA IR
Jan 30, 2026	Q3 Tanshin + Presentation	Q3 FY25 results + Share Buyback #2 announcement (¥100B) + Dividend increase	Presentation

Filing activity: Elevated and shareholder-friendly. Record results + ¥100B second buyback announced + major dividend increase.

2. Q3 FY25 Results (Quarter Ended December 31, 2025)

Consolidated Headline (Q3 Standalone)

Metric	FY24 Q3	FY25 Q3	YoY	CC YoY
Revenue	¥219.4B*	¥244.7B	+11%	+8%
Operating Profit	¥66.2B*	¥74.1B	+12%	+11%
OP Margin	~30.2%	30.3%	flat	—
Pretax Profit	¥65.3B*	¥110.8B	+70%	+68%
ROIC	—	23.0%	—	—

*Prior year estimated from TTM data. FX: USD 155.76 (-1.0%), EUR 181.41 (-10.9%).

All three metrics — revenue, operating profit, and pretax profit — reached record highs. Both Life Care and IT achieved double-digit revenue growth. Pretax profit surged +70% partly from one-off factors: IOL JV gain (China acquisition cost below estimate), gains on business transfers, and FX gains.

Life Care Business — Q3 Standalone

Metric	FY24 Q3	FY25 Q2	FY25 Q3	QoQ	YoY
Revenue	¥139.4B	¥146.9B	¥151.5B	+3.1%	+9% (CC +4%)
OP	¥24.7B	¥25.9B	¥27.4B	+5.8%	+11%
OP Margin	17.7%	17.6%	18.1%	+0.5pts	+0.4pts
Pretax	¥19.0B	¥24.1B	¥53.8B	+123%	+183%

Sub-segment growth (Q3 YoY, CC in parentheses):

• Eyeglass Lenses: +11% (CC +6%) — Japan, Eastern Europe, Latin America drove growth. China returned to YoY growth for first time in 4 quarters as MiYOSMART counterfeit impact lapped. New high-value-added product pipeline for next FY.
• Contact Lenses (eyecity): +4% (CC +4%) — ASP growing from 1-day lens shift and high-value products.
• IOLs: +11% (CC +6%) — Europe recovering from Q1 disruption. Japan monofocal resilient. Vivinex multiSert highlighted.
• Endoscopes: -4% (CC -10%) — the weak spot. Europe/US declined from competitor discounting and bundling. China uncertain. Structural reforms (org streamlining, cost cuts) progressing.
• Artificial Bone & Other: +20% (CC +15%) — endoscope washers, artificial bones, metal implants, chromatography media all strong.

Information Technology Business — Q3 Standalone

Metric	FY24 Q3	FY25 Q2	FY25 Q3	QoQ	YoY
Revenue	¥80.4B	¥86.5B	¥92.9B	+7.4%	+16% (CC +15%)
OP	¥43.2B	¥46.0B	¥49.3B	+7.2%	+14%
OP Margin	53.7%	53.1%	53.0%	-0.1pts	-0.7pts
Pretax	¥45.0B	¥47.8B	¥51.4B	+7.5%	+14%

53% operating margin on a +16% growth business. This is one of the highest-quality technology businesses in Japan. Revenue increased across all products, with blanks and imaging showing mid-teens growth. Margins stayed above 53% despite increased depreciation.

Sub-segment growth (Q3 YoY):

• LSI (Photomask Blanks): +14% (CC +14%) — EUV blanks maintained double-digit growth from active customer development at advanced nodes. DUV blanks robust across applications including EUV lithography usage, Chinese customers, and memory. Targeting higher-value phase shift masks for next-gen.
• FPD (Flat Panel Display Photomasks): +15% (CC +15%) — rebound from prior year sluggishness, improved China plant capacity. Smartphone and IT OLED masks particularly strong.
• HDD Substrates: +9% (CC +8%) — 3.5-inch substrates continued double-digit growth. CSP demand "exceptionally high," no cyclical deterioration seen. Q4 expected to see only slight decrease. Capacity expansion planned beyond FY26 — data center demand is structural.
• Imaging: +35% (CC +33%) — wearable camera lenses surging on social media/AI demand, driven by CUPO material. Digital camera products also up from mirrorless launches.

CUPO — New AI/Data Center Growth Driver

HOYA dedicated two pages of the presentation to CUPO (Copper-doped Polarized Optics), signaling its strategic importance:

• Optical component with polarization properties from trace copper doping
• Essential for efficient optical data transmission without loss in optical transceivers, modulators, wavelength selectors
• AI expansion → sharp increase in optical transceiver shipments (400G → 800G → 1.6T)
• Number of CUPO chips per transceiver unit is rising as data speeds increase — structural volume multiplier
• Broad customer base spanning US and Chinese companies
• Long history (mentioned in 2009 Annual Report) but demand inflecting now due to AI data center buildout

This is HOYA's direct AI/data center play — analogous to Anritsu's 800GE/1.6TE instruments and Rigaku's semi metrology tools.

6. Guidance

Q4 FY25 (Jan-Mar 2026)

Metric	FY24 Q4	FY25 Q4E	YoY
Revenue	¥216.8B	¥240.4B	+11%
Operating Profit	¥65.7B	¥71.5B	+9%
Pretax Profit	¥67.7B	¥73.9B	+9%
Net Profit	¥51.1B	¥56.5B	+11%

• Life Care: stable performance expected
• IT: smaller-than-usual QoQ revenue decline due to sustained high demand

Full Year FY25 (Apr 2025 - Mar 2026)

Metric	FY24 Actual	FY25E Guide	YoY
Revenue	¥866.0B	¥940.0B	+9%
Operating Profit	¥255.8B	¥282.0B	+10%
Pretax Profit	¥260.0B	¥324.0B	+25%
Net Profit	¥201.8B	¥254.0B	+26%

Both revenue and profit expected to reach record highs on an annual basis.

Full year guide of ¥940B revenue beat consensus of ¥925.4B. Net profit guide of ¥254B is well above expectations. The pretax/net profit growth (+25-26%) significantly exceeds OP growth (+10%) due to one-off gains flowing through.

Shareholder Returns

HOYA is returning capital at an exceptional rate:

Program	Period	Amount	Status
Buyback #1	Aug 22 - Dec 1, 2025	~¥100B	Completed, all shares cancelled
Buyback #2	Feb 2 - Jul 17, 2026	Up to ¥100B	In progress, will cancel after
Total buybacks	FY25	~¥200B	—
Interim dividend	—	¥125/share (+¥80 vs PY)	Paid
Interim dividend total	—	¥42.5B (+¥26.9B)	—
Year-end dividend	—	TBD	—
Dividend policy	—	Progressive, targeting 40% payout	—

Management explicitly states: "The plan is to avoid increasing the annual cash and deposits level through aggressive shareholder returns." This is about as shareholder-friendly as a Japanese company gets.

9. Red Flag Alerts

Red Flag	Detected?	Details
Going concern	No	—
Endoscope weakness	Monitor	-4% revenue (-10% CC) from competitor discounting. Structural reforms underway but this is a multi-quarter headwind
Pretax profit quality	Context	Pretax +70% includes one-off IOL JV gain, business transfer gains, and FX gains. Underlying OP growth is +12% — still strong but less dramatic than pretax suggests
Valuation	Monitor	P/E 34.9x vs industry 15.7x, above DCF fair value of ¥20,914 vs price ¥25,870. Premium is earned by quality but priced for perfection

No red flags. The endoscope weakness is a competitive issue, not structural — and it's a small portion of the portfolio relative to the growing eyeglass/IOL/IT businesses.

10. Key Takeaways

1. HOYA is executing across the board. Record revenue, record OP, record pretax profit in Q3. Both segments growing double digits. IT margins at 53% are extraordinary. Life Care margins expanding to 18.1%.

2. IT segment is the AI/semi play within HOYA. EUV blanks (+14%), HDD substrates (+9%, nearline/data center driven), FPD photomasks (+15%), and the CUPO imaging material (+35%) are all benefiting from AI infrastructure investment. The 53% OP margin means almost every dollar of IT revenue growth drops to the bottom line.

3. CUPO is the emerging AI data center angle. Copper-doped polarized optics are essential for optical transceivers, and volume per transceiver is rising as data speeds increase. This is a structural growth driver tied to the 400G → 800G → 1.6T transition — the same tailwind benefiting Anritsu's T&M business.

4. Shareholder returns are exceptional. ¥200B in buybacks + ¥125 interim dividend (up from ¥45) in a single year. Management is explicitly committed to not accumulating excess cash. For a Japanese company, this level of capital return discipline is rare.

5. Endoscopes are the sole weak spot. -10% CC growth from competitor discounting/bundling (likely Olympus). HOYA is pursuing structural reforms (cost cuts, organizational streamlining) but this is a competitive fight, not a quick fix. Still, it's a small drag on an otherwise outstanding portfolio.

11. Investment Implications

Does this change the thesis? Confirms HOYA as one of the highest-quality Japanese companies. The combination of healthcare stability (eyeglass lenses, IOLs) and technology growth (EUV blanks, CUPO, HDD substrates) is unique. The IT segment's 53% operating margin gives extraordinary earnings leverage on revenue growth.

Single most important takeaway: The CUPO story is the new angle. HOYA has always been known for EUV blanks and HDD substrates, but CUPO as an AI data center play (polarized optics for optical transceivers, volume multiplying with speed increases) adds another growth vector to the IT segment. The fact that management dedicated two presentation pages to it signals strategic importance.

What to watch for full-year results (May 13, 2026):

1. FY26 guidance: does management guide for continued double-digit growth?
2. CUPO revenue trajectory — can they quantify the opportunity?
3. HDD substrate capacity expansion details — timeline, capex, expected revenue contribution
4. Endoscope restructuring progress — when does this segment stabilize?
5. Buyback #2 completion status and any Buyback #3 announcement

Action: HOLD. At 34.9x trailing P/E, HOYA trades at a premium to both the Japanese market and global medtech peers. The quality is undeniable — 53% IT margins, 23% ROIC, ¥200B in buybacks — but the stock is priced for perfection above the ¥20,914 DCF fair value at ¥25,870. This is a compounder you own for the long term, not one you chase at all-time highs. Any pullback toward ¥20,000-22,000 would be a gift.

---

Sources: HOYA IR, Q3 Presentation, Simply Wall St, MarketScreener

---

Topics

• ai-infrastructure
• optical-components
• japan-semi